Improved method for analysis of cysteinyldopa in human serum

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 64, Issue 6, 2004, Pages 559-564

  Arstrand K ^a   Kullman, A ^a   Andersson, R ^b   Rasmuson, T ^b   Kagedal B ^a,c  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

5 S D cysteinyl L dopa; 5 S L cysteinyl L dopa; Boronate affinity gel; High performance liquid chromatography

Indexed keywords

BORONIC ACID DERIVATIVE; CYSTEINYLDOPA; HYDROXYL GROUP; PEGINTERFERON ALPHA2B; TEMOZOLOMIDE; VERAPAMIL;

ACCURACY; AGED; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; CASE REPORT; DIASTEREOISOMER; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MELANOMA; PEPTIDE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VALIDATION PROCESS;

AGED; CHEMISTRY, CLINICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINYLDOPA; HUMANS; MELANOMA; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS;

EID: 4844225013     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510410007026     Document Type: Article

References (18)

1. Banfalvi T, Gilde K, Boldizsar M, Kremmer T. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma 2002; 49: 121-5.
2. Kärnell R, Kågedal B, Lindholm C, Nilsson B, Årstrand K, Ringborg U. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 2000; 10: 363-9.
3. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997; 57: 5073-6.
4. Banfalvi T, Gilde K, Boldizsar M, Fejos Z, Horvath B, Liszkay G, Beczassy E, Kremmer T. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur J Clin Invest 2000; 30: 900-4.
5. Horikoshi T, Ito S. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression. J Dermatol 1992; 19: 809-13.
6. Kärnell R, von Schoultz E, Hansson LO, Nilsson B, Årstrand K, Kågedal B. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole- 2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 1997; 7: 393-9.
7. Sasaki Y, Shimizu H, Naka W, Takeshita E, Nishikawa T. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients. Acta Derm Venereol 1997; 77: 379-81.
8. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73: 629-36.
9. Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, Ono T, Saida T, Takata M, Tsuchida T, Uhara H, Yamamoto A, Yamazaki N, Naito A, Ito S. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res 2002; 12: 245-53.
10. Banfalvi T, Gilde K, Gergye M, Boldizsar M, Kremmer T, Otto S. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer 2003; 39: 164-9.
11. Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S. Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 2002; 8: 183-7.
12. Kågedal B, Källberg M, Årstrand K, Hansson C. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4- dihydroxyphenylalanine in urine. J Chromatogr 1989; 473: 359-70.
13. Kågedal B, Pettersson A. Determination of 5-S-L-cysteinyl-L-dopa in serum by high-performance liquid chromatography after prepurification with immobilized boric acid. In: Bagnara J, Klaus SN, Paul E, Schartl M, editors. Pigment Cell 1985. Biological, molecular and clinical aspects of pigmentation. Tokyo: University of Tokyo Press; 1985. p. 721-7.
14. Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to high-performance liquid chromatographic analysis. J Chromatogr 1981; 226: 455-60.
15. Kågedal B, Pettersson A. Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with electrochemical detection in urine prepurified with a phenylboronate affinity gel. Clin Chem 1983; 29: 2031-4.
16. Agrup G, Edholm LE, Rorsman H, Rosengren E. Diastereomers of 5-S-cysteinyldopa. Acta Derm Venereol 1983; 63: 59-61.
17. Hartleb J, Damm Y, Arndt R, Christophers E, Stockfleth E. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction - high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma. J Chromatogr B Biomed Sci Appl 1999; 727: 31-42.
18. Wakamatsu K, Ito S. Improved HPLC determination of 5-S-cysteinyldopa in serum. Clin Chem 1994; 40: 495-6.